For the Rest

Johnson & Johnson bid 1.75 billion euros to buy the rest of the Dutch biotechnology company Crucell, reports The New York Times' DealBook, which notes that Johnson & Johnson already owns nearly 18 percent of the biotech. The offer for the company, which specializes in vaccines and therapeutics for infectious diseases, is 24.75 euros a share, and is supported by the Crucell board. The bid goes to a vote in early February.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.